Neuroscience and oncology fuel high hopes for therapeutic R&D progress among 90-plus surveyed biopharma industry leaders.

When the traditional fundraising window closes and clinical, regulatory or commercial success eludes, other routes to raise cash emerge. But these have also become more scarce recently, leaving all-stock consolidations.

Previously jailed gene editing scientist Jiankui He was absent from a recent international genome editing summit, but his renewed activities are generating new concerns five years after the Chinese researcher shocked the world by announcing the birth of gene-edited babies.  

Solanezumab did not reduce the risk of progression in preclinical Alzheimer’s disease in the Phase III A4 study but it provided evidence that removing amyloid plaques – the mechanism of action for Lilly’s two remaining Phase III AD therapies, donanemab and remternetug – may be the key to efficacy.